Welcome to AstraZeneca United States
Beginning its journey in 1953, AstraZeneca became one of the first pharmaceutical companies operating in the United States
Latest News from AstraZeneca United States
FDA grants fast track designation for FARXIGA in heart failure
AstraZeneca today announced that the US Food and Drug Administration (FDA) has granted Fast Track designation for the development of FARXIGA (dapagliflozin) to reduce the risk of cardiovascular (CV) death or the worsening of heart failure in adults with heart failure with reduced ejection fraction (HFrEF) or preserved ejection fraction (HFpEF).
@AstraZenecaUS on Twitter
RT @SHAREing: Did you know that #ovariancancer can be hereditary? Research shows that most women who carry either the BRCA1 or BRCA2 gene m…
RT @LearningUNDFTD: #STEM de-mystified in NEW #k12 #education program #GenerationHealthAZ. Spark curiosity in subjects like #oncology #medi…
In chronic lymphocytic #leukemia (CLL), #cancer cells survive better than normal cells, leaving less room for healt… https://t.co/vShcWc81pT
Detailed results from Phase III DAPA-HF trial showed FARXIGA significantly reduced both the incidence of cardiovascular death and the worsening of heart failure
DAPA-HF is the first outcomes trial with an SGLT2 inhibitor in patients with heart failure with reduced ejection fraction, with and without type 2 diabetes
BRILINTA reduced the risk of cardiovascular events in patients with coronary artery disease and type 2 diabetes in Phase III THEMIS trial
AstraZeneca today announced detailed results from the positive Phase III THEMIS trial, which showed BRILINTA (ticagrelor) plus aspirin reduced the relative risk for the composite of cardiovascular (CV) death, heart attack, or stroke by 10% (7.7% vs 8.5%) compared with aspirin alone, a statistically significant reduction.
Latest AZ&You Blog Articles
Our Favorites from 2016 – Highlights of the AZ&You Blog
Throughout 2016 on our blog, we shared interviews with patients; news about partnerships and initiatives that help support patients and science; stories that illustrate our focus on advancing patient health and access to care; and much more. From the dozens of blog posts we published this year, we put together a list of some of our favorites that we want to make sure you catch before the year is over.
Stigma, Genetics and Hope: 11 Years with Lung Cancer
In 2005, Melissa Crouse was diagnosed with lung cancer and given three to five years to live. Eleven years later, Melissa continues to manage her disease while giving back to the lung cancer community and getting the most out of life. Melissa shares her perspective on living with lung cancer, understanding the importance of biomarkers, and remaining hopeful.
What Does the New CancerLinQ Discovery Initiative Mean for the Future of Patient Care?
By Kevin Fitzpatrick, CEO, CancerLinQ LLC
This is an exciting time in the field of oncology—a time of rapid discovery, learning and new treatments to fight this terrible disease, as we work to provide patients with greater hope. Imagine taking these daily learnings and aggregating them in one accessible place while simultaneously creating a learning platform that medical oncologists can use to help improve patient care.
Personalized Healthcare: What It Means and Why It Matters
When it comes to cancer treatment, one size does not fit all. Of the estimated 1.6 million Americans who will be diagnosed with cancer in 2016, no two will be exactly the same. More and more, we’re hearing (and using) buzzwords to this effect: Personalized healthcare. Precision medicine. Targeted therapy.
What Getting ON IT Means to Me for American Diabetes Month®
By Dr. Phil McGraw
As someone who has lived with type 2 diabetes for more than 25 years, I understand the day-to-day issues that accompany managing a lifelong disease. It’s important to me to amplify the conversation around these challenges that people living with type 2 diabetes experience.
How the Type 2 Diabetes Patient Community is Unifying their Voice Online
While online conversations about diabetes are on the rise and people with diabetes have cultivated the Diabetes Online Community (#DOC) as a way to connect with one another, those living with type 2 diabetes seem to play a less active part in the dialogue. To help strengthen and elevate the voices of type 2 diabetes advocates, AstraZeneca recently hosted members of the type 2 community for DiabetesLinkup: In It 2gether.
AstraZeneca Gives Back: Advancing Respiratory Health Beyond the Medicine
“Before being diagnosed with COPD, I lived a dramatically wonderful life. As my disease has progressed, it’s become harder for me to do the things I never thought twice about,” shares Edna Shattuck, a Chronic Obstructive Pulmonary Disease (COPD) patient and retired nurse in Chevy Chase, MD. Edna is one of more than 15 million Americans diagnosed with COPD, the third leading cause of death in the United States and the second leading cause of disability.
Protecting Your Child’s Lungs this RSV Season
As seasonal viruses begin to circulate this autumn, there is no better time to educate new and expecting parents of a common virus contracted by nearly 100 percent of infants by the age of two – Respiratory Syncytial Virus (RSV). RSV disease is the leading cause of hospitalization for babies in the US during their first year of life, and can cause up to approximately 200 infant deaths in the US each year.
Navigating Cancer Clinical Trials: Where to Start
When patients are diagnosed with cancer, the following questions may be top of mind as they begin their treatment journey: Should I consider joining a clinical trial? What does clinical trial participation entail? How can I locate the most appropriate clinical trial for my particular disease? How do I actually enroll in a clinical trial?
One Brave Idea $75 Million Research Award for Coronary Heart Disease Winner Announced
AstraZeneca, the American Heart Association (AHA) and Verily (formerly Google Life Sciences) announced Wednesday that Dr. Calum MacRae is the recipient of a $75 million research award to study coronary heart disease (CHD) and its consequences.
18 Years Strong: Living with Metastatic Breast Cancer
When doctors diagnosed Kristin Johnson St. Goddard with metastatic breast cancer, she was given 18 months to live. Fast forward 18 years and different treatment regimens - Kristin is still going strong. While some days are challenging, she continues to lead a good life, and remains hopeful that one day, there will be a cure. See her story.
New Resource Offers 24/7 Support for those with Mental Illness
Nine years ago, Danei Edelen was established in her career as a marketing executive and happily raising a family with her husband in Ohio. Then something unexpected happened. “After five nights of no sleep, hallucinations, I sought hospitalization,” Danei said. She subsequently learned she had experienced a psychotic break caused by an underlying and undiagnosed mental illness called bipolar disorder.
The Power of Diversity Celebrated at AstraZeneca’s 5th Annual Women’s Summit
“Leadership is surrounding yourself with others who do not think like you and bringing out the best in those people.”
“Fostering diversity does not need justification; it is simply the right thing to do.”
“Diversity fuels innovation; a team needs individuals who approach challenges differently.”
These messages were among those heard by hundreds of our employees last month at the 5th Annual Women’s Summit held on our Gaithersburg campus.
Connecting the Dots of Hereditary Cancer
By Sue Friedman, DVM, founder and Executive Director, Facing Our Risk of Cancer Empowered (FORCE)
In 1996, at the age of 33, I was diagnosed with breast cancer. My diagnosis came out of the blue. I was otherwise healthy, and only one relative, my grandmother, in my small family tree had also had cancer. My doctors didn’t appreciate how significant that one relative could be, and my health care team didn’t mention genetic testing. I had no idea that my cancer could be hereditary.
Making Medicine Personal in Cancer Treatments
Cancer is one of mankind’s greatest scientific and health challenges. Today, nearly 14.5 million Americans have cancer and the total annual cost of their treatment is estimated at $125 billion. With astonishing numbers like these, it’s more important than ever before that patients receive the best care possible while effectively managing overall costs to the healthcare system.
Interactive Teaching Model Engages Students in STEM
Not long ago, Emma Waldman was a fifth grader just outside of Boston, Massachusetts, disengaged from her classes in science and math. “[They] were always hard to conceptualize, I never really saw them as practical or important,” says Emma. She is certainly not alone; 83% of students in the United States are not proficient or not interested in science, technology, engineering and math (STEM) fields by eighth grade.
Making Medicine Personal in Cardiovascular and Metabolic Health
Cardiovascular and metabolic diseases are complex and require life-long attention. Patients need to address many factors — from preventive measures, to care at the onset of disease to ongoing disease management. Our goal at AstraZeneca is to reduce the high cost of long-term complications with comprehensive support programs and resources that provide a thoughtful, personalized approach. We do this to help patients adhere to their treatment, reduce re-admission rates and change the course of disease by improving quality of care and ensuring that innovative medicines are being researched and accessible to patients in a timely manner.
Mobile Savings and Support App Offers Patients New Ways to Manage Health
When managing your health, convenience is key. We all want tools that enable us to lead healthier lives while saving us time and money. That’s why AstraZeneca is introducing an industry leading digital support program called AZhelps, built to help you better manage your AstraZeneca medications and your health.
Patient influencers bring medical meetings to life online
We recently took a look at how social media has transformed medical meetings, enabling attendees to engage and connect in real time, but also allowing anyone with internet access to join the conversation from wherever they are. As we approach the American Diabetes Association’s 76th Scientific Sessions taking place June 10-14, those at the meeting will take to social media to share their #2016ADA experience with the world, from new research presented to exploring New Orleans and everything in between.
Harnessing the Immune System to Potentially Revolutionize Cancer Treatment for Patients
This year alone, nearly 1.7 million new cancer cases are expected to be diagnosed in the United States. A patient newly diagnosed with cancer, after absorbing the unwanted news from his or her physician, will want to know, “What treatments will I need? Where do I begin?”
Purposeful Collaboration: Teaming Up to Increase Community Impact
AstraZeneca recently hosted a number of non-profit partners at our North America Headquarters in Wilmington, Delaware for an event, entitled Purposeful Collaboration, which was developed based on their interest in collaborating across organizational lines for greater impact.
Making Medicine Personal in Respiratory Health
Your health and that of your loved ones is one of the most important aspects of life. It’s also the most important aspect of our work. For more than 40 years, we’ve addressed respiratory challenges to improve millions of lives – and we’re not slowing down.
Asking Congress to Get “On It” for Diabetes
By Topher Brooke, Vice President, U.S. Diabetes, AstraZeneca
On May 11, AstraZeneca and Dr. Phil will join policymakers and advocates on Capitol Hill to ask Congress for more support of those living with and at risk for developing diabetes and call attention to the patient experience.
“I had no idea that there were other forms of constipation” – a Patient’s OIC Story
For patients with chronic pain, taking a prescribed opioid treatment for long-term pain management may provide pain relief but can also cause opioid-induced constipation (OIC). However, some patients may not realize that constipation is one of the most common side effects of their prescription opioid treatment.
A Patient’s Perspective during Oral, Head and Neck Cancer Awareness Week
By Jessica Tar, patient advocate
2010 was truly a year that delivered the worst to my life. In April, the unexpected death of my father, a non-smoker, from lung cancer, revealed the mystery of this disease and at times, its unidentifiable origins. My shock was to be exceeded just nine months after my father’s death when I received the news of my own diagnosis of squamous cell carcinoma.
Why People with Type 2 Diabetes Should Start a Walking Program
Today, more than 145 million adults in the United States include walking as part of a physically active lifestyle, and this staple exercise continues to grow in popularity. After all, walking can be done just about anywhere and, for most, is as simple as putting one foot in front of the other.
Perspectives on Cardiovascular Disease: a Multi-Faceted Condition
By Steven Zelenkofske, DO, Vice President, US Medical Affairs, Cardiovascular, AstraZeneca
With ACC coming up this weekend, I caught up with Roxana Mehran, MD, of Mount Sinai School of Medicine to discuss the multi-faceted nature of cardiovascular disease (CVD) and how research and science is helping to evolve the way we view the causes and management of CVD.
Bringing Medical Meetings to Everyone via Social Media
Social media takes medical meetings beyond the convention center walls to provide a real-time yet enduring story of patient experiences, scientific breakthroughs and inspirational speakers. It opens the meetings up to anyone, whether they have a deep or passing interest in all or any of the subjects being discussed, while democratizing the sharing of information.
If you are passionate about science, these stories will show you how the latest and most exciting projects we have been working on and the people behind them.